AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-Start (SS: 100 mW/cm(2) x 10s + 600 mW/cm(2) x 30s)
Number of subjects: 2
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-Delay (PD: 100 mW/cm(2) x 3s + 3 min wait + 600 mW/cm(2) x 37s)
Number of subjects: 2
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional (CO: 400 mW/cm(2) x 40s)
Number of subjects: 2
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB) adhesive system
Number of subjects: 2
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CE) adhesive system with SS technique
Number of subjects: 2
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-Delay (PD) in microhardness test
Number of subjects: 2
Study 16098575 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional (CO) in microhardness test
Number of subjects: 2
Study 14597591 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 123
Study 14597591 — intervention group
Group type: COMPARATOR
Intervention: Accelerated tPA
Number of subjects: 123
Study 10879765 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF with pedicle screws and TFCs
Number of subjects: 10
Study 10879765 — intervention group
Group type: COMPARATOR
Intervention: Anterior discectomy with unilateral cage
Number of subjects: 10
Study 10879765 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior implantation of bilateral TFCs
Number of subjects: 10
Study 9356027 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.92 micromol (100 microg) Cr as chromium picolinate two times per day
Number of subjects: 180
Study 9356027 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6 micromol (500 microg) Cr two times per day
Number of subjects: 180
Study 9356027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8249562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml epidural blood patch (EBP)
Number of subjects: 81
Study 8249562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-15 ml epidural blood patch (EBP)
Number of subjects: 81
Study 8249562 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml and 10-15 ml epidural blood patch (EBP)
Number of subjects: 81
Study 3861069 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra early contact beginning approximately one-half hour after delivery
Number of subjects: 78
Study 3861069 — intervention group
Group type: COMPARATOR
Intervention: Regular contact
Number of subjects: 78
Study 29870578 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330672 (10-180 mg)
Number of subjects: 16
Study 29870578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28829936 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg)
Number of subjects: 50
Study 28829936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26466590 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group
Number of subjects: 87
Study 26466590 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group
Number of subjects: 87
Study 26466590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 23635914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 to 1.5 mg) intravenously
Number of subjects: 398
Study 23635914 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 398
Study 21385882 — intervention group
Group type: EXPERIMENTAL
Intervention: E(dd)→T(dd)→CMF
Number of subjects: 370
Study 21385882 — intervention group
Group type: COMPARATOR
Intervention: EC→T
Number of subjects: 370
Study 21385882 — intervention group
Group type: EXPERIMENTAL
Intervention: DA
Number of subjects: 370
Study 21385882 — intervention group
Group type: COMPARATOR
Intervention: No DA
Number of subjects: 370
Study 19277410 — intervention group
Group type: EXPERIMENTAL
Intervention: DAWN AC computer-assisted dosage program
Number of subjects: 2631
Study 19277410 — intervention group
Group type: COMPARATOR
Intervention: Manual dosage by experienced medical staff
Number of subjects: 2631
Study 18317605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive with estriol (group 2)
Number of subjects: 33
Study 18317605 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive without estriol (group 1)
Number of subjects: 33
Study 15164963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g daily
Number of subjects: 529
Study 15164963 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam 3.375 g Q6H
Number of subjects: 529
Study 11479053 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education program for type 2 diabetes
Number of subjects: 105
Study 9777816 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling (4 interactive theory-based sessions)
Number of subjects: 5758
Study 9777816 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling (2 interactive risk-reduction sessions)
Number of subjects: 5758
Study 9777816 — intervention group
Group type: COMPARATOR
Intervention: Didactic messages (2 brief messages typical of current care)
Number of subjects: 5758
Study 9777816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both counseling interventions (Enhanced and Brief)
Number of subjects: 5758
Study 7873470 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril treatment for 20 weeks
Number of subjects: 17
Study 2450255 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (150 mg t.d.s.)
Number of subjects: 13
Study 2450255 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg t.d.s.)
Number of subjects: 13
Study 30630844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF)
Number of subjects: 399
Study 30630844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 29299520 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation lavender aromatherapy
Number of subjects: 100
Study 29299520 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care (Control)
Number of subjects: 100
Study 25801891 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (4000 IU, orally given as four gel capsules of 1000 IU)
Number of subjects: 80
Study 25801891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22952305 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with neuromuscular electrical stimulation (biphasic pulses, at 75 Hz and 250 µs phase duration)
Number of subjects: 50
Study 22952305 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only group
Number of subjects: 50
Study 20542923 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg TC-1734 (AZD3480)
Number of subjects: 193
Study 20542923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 19379973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 arterial grafts (left thoracic artery plus right thoracic artery or left thoracic artery plus radial artery)
Number of subjects: 815
Study 19379973 — intervention group
Group type: COMPARATOR
Intervention: 1 arterial graft (control group)
Number of subjects: 815
Study 17244633 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 155000
Study 14750322 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU for 6 months
Number of subjects: 155
Study 14750322 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFU for 2 years
Number of subjects: 155
Study 12795454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.i.d.
Number of subjects: 21
Study 12795454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10200896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PROP, without ISA, 160 mg q.d.)
Number of subjects: 30
Study 10200896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (PIN, with potent ISA, 15 mg q.d.)
Number of subjects: 30
Study 10200896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, q.d.)
Number of subjects: 30
Study 7768077 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg (R,S)-propranolol
Number of subjects: 12
Study 7768077 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg (R)-propranolol
Number of subjects: 12
Study 7768077 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg (S)-propranolol
Number of subjects: 12
Study 7768077 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg (R,S)-atenolol
Number of subjects: 12
Study 7768077 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg (R)-atenolol
Number of subjects: 12
Study 7768077 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg (S)-atenolol
Number of subjects: 12
Study 7768077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2109980 — intervention group
Group type: EXPERIMENTAL
Intervention: A mixture of amino acids, glucose and lipids
Number of subjects: 15
Study 2109980 — intervention group
Group type: COMPARATOR
Intervention: A mixture of amino acids and glucose
Number of subjects: 15
Study 120091 — intervention group
Group type: EXPERIMENTAL
Intervention: Blow-bottles
Number of subjects: 98
Study 120091 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative pulmonary physiotherapy
Number of subjects: 98
Study 31965885 — intervention group
Group type: COMPARATOR
Intervention: Placebo Response (PR) measured by TOVA-ACS
Number of subjects: 0
Study 31965885 — intervention group
Group type: COMPARATOR
Intervention: Placebo Response (PR) measured by CAARS
Number of subjects: 0
Study 31965885 — intervention group
Group type: EXPERIMENTAL
Intervention: TOVA-PR
Number of subjects: 0
Study 31965885 — intervention group
Group type: EXPERIMENTAL
Intervention: TOVA-MPH-R
Number of subjects: 0
Study 31978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (400 mg/kg loading dose followed by 200 mg·kg·day maintenance for 5 days)
Number of subjects: 86
Study 31978010 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy with placebo
Number of subjects: 86
Study 31978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate
Number of subjects: 86
Study 31353457 — intervention group
Group type: EXPERIMENTAL
Intervention: MDZ-NS 5 mg (single dose)
Number of subjects: 175
Study 31353457 — intervention group
Group type: EXPERIMENTAL
Intervention: MDZ-NS 5 mg (second dose if needed)
Number of subjects: 175
Study 31353457 — intervention group
Group type: EXPERIMENTAL
Intervention: MDZ-NS
Number of subjects: 175
Study 30141210 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with defibrillator (CRT-D)
Number of subjects: 756
Study 26818913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based video intervention (5-minute movies)
Number of subjects: 300
Study 26818913 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 300
Study 24634346 — intervention group
Group type: EXPERIMENTAL
Intervention: AT/IMT (Aerobic Training with Inspiratory Muscle Training)
Number of subjects: 43
Study 24634346 — intervention group
Group type: COMPARATOR
Intervention: AT/SHAM (Aerobic Training with Sham Inspiratory Muscle Training)
Number of subjects: 43
Study 21659435 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 2 × 250 mg daily
Number of subjects: 45
Study 21659435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20659072 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessed condition (n = 152)
Number of subjects: 446
Study 20659072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (n = 147)
Number of subjects: 446
Study 20659072 — intervention group
Group type: COMPARATOR
Intervention: Screened-only condition (n = 147)
Number of subjects: 446
Study 20659072 — intervention group
Group type: COMPARATOR
Intervention: Assessment condition (n = 152)
Number of subjects: 446
Study 20659072 — intervention group
Group type: COMPARATOR
Intervention: All groups (screened-only, assessed, intervention)
Number of subjects: 446
Study 17653742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (100 mg)
Number of subjects: 52
Study 17653742 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine (50 mg)
Number of subjects: 52
Study 16297755 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% N2O in O2 via facemask
Number of subjects: 60
Study 16297755 — intervention group
Group type: COMPARATOR
Intervention: 100% O2 via facemask
Number of subjects: 60
Study 11932297 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.06 mg/kg.d)
Number of subjects: 60
Study 11932297 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.03 mg/kg.d)
Number of subjects: 60
Study 11932297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9704789 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcriptase‐polymerase chain reaction
Number of subjects: 35
Study 9704789 — intervention group
Group type: COMPARATOR
Intervention: Genomic‐polymerase chain reaction
Number of subjects: 35
Study 8554838 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone pessaries (400 mg twice a day)
Number of subjects: 141
Study 8554838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 30573480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with an ACE inhibitor (perindopril) and a beta-blocker (bisoprolol)
Number of subjects: 0
Study 30573480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27683297 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate aggressive physiotherapy (Group A)
Number of subjects: 220
Study 27683297 — intervention group
Group type: COMPARATOR
Intervention: Delayed aggressive physiotherapy (Group B)
Number of subjects: 220
Study 26646251 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day training intervention 'Older People's Shoes' for healthcare assistants
Number of subjects: 0
Study 26646251 — intervention group
Group type: COMPARATOR
Intervention: Training as usual (Control)
Number of subjects: 0
Study 23620421 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 56
Study 23620421 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 56
Study 21063906 — intervention group
Group type: COMPARATOR
Intervention: Corn gluten meal (CGM) at 200 g kg⁻¹
Number of subjects: 0
Study 21063906 — intervention group
Group type: COMPARATOR
Intervention: Corn gluten meal (CGM) at 100 g kg⁻¹
Number of subjects: 0
Study 21063906 — intervention group
Group type: COMPARATOR
Intervention: Corn gluten meal (CGM) at varying concentrations (0 to 200 g kg⁻¹)
Number of subjects: 0
Study 18578300 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based cognitive fear reduction (ABCF) procedure
Number of subjects: 266
Study 18578300 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 266
Study 16492915 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 27
Study 16492915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12646971 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (10 mg/kg)
Number of subjects: 17
Study 12646971 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 17
Study 10883413 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 30
Study 10883413 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG-N
Number of subjects: 30
Study 10883413 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG-L
Number of subjects: 30
Study 9179659 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT adjuvant therapy (1:4 mixture of tegafur and uracil)
Number of subjects: 66
Study 9179659 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvant therapy
Number of subjects: 66
Study 1490666 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) alone, 2.6 IU/m2 body surface area daily
Number of subjects: 91
Study 1490666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with rhGH (2.6 IU/m2 daily) and oxandrolone (0.1 mg/kg body weight orally)
Number of subjects: 91
Study 1490666 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) alone, increased dose to 3.4 IU/m2 daily
Number of subjects: 91
Study 1490666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with rhGH (3.4 IU/m2 daily) and reduced oxandrolone (0.05 mg/kg daily)
Number of subjects: 91
Study 3966331 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg flecainide
Number of subjects: 22
Study 3966331 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg flecainide
Number of subjects: 22
Study 3966331 — intervention group
Group type: COMPARATOR
Intervention: Flecainide diluent
Number of subjects: 22
Study 30545337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric dentists (PDs)
Number of subjects: 588
Study 30545337 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric dentists (PDs) aged 40 years or younger
Number of subjects: 588
Study 30545337 — intervention group
Group type: COMPARATOR
Intervention: General dental practitioners (GDPs)
Number of subjects: 588
Study 30545337 — intervention group
Group type: EXPERIMENTAL
Intervention: General dental practitioners (GDPs) and paediatric dentists (PDs)
Number of subjects: 588
Study 28322235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan Depletion (TD)
Number of subjects: 33
Study 28322235 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study 28322235 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol treatment
Number of subjects: 33
Study 26604001 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme Peer-delivered (THPP) - 10 individual and 4 group sessions in Pakistan or 6-14 individual sessions in India
Number of subjects: 840
Study 26604001 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 840
Study 26604001 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Programme Peer-delivered (THPP)
Number of subjects: 840
Study 24075274 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSA with a bipolar sealer (Aquamantys 2.3 Bipolar Sealer); n = 55
Number of subjects: 109
Study 24075274 — intervention group
Group type: COMPARATOR
Intervention: CUSA with standard bipolar cautery (BC); n = 54
Number of subjects: 109
Study 21163550 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus biometric feedback
Number of subjects: 0
Study 21163550 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus biometric feedback and dermatologist skin examination
Number of subjects: 0
Study 21163550 — intervention group
Group type: COMPARATOR
Intervention: Education only
Number of subjects: 0
Study 21163550 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus dermatologist skin examination
Number of subjects: 0
Study 18331935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular cervical headgear (MCH) therapy followed by fixed appliances
Number of subjects: 21
Study 18331935 — intervention group
Group type: COMPARATOR
Intervention: Untreated Class III controls
Number of subjects: 21
Study 16641265 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x pTHr.HIVA followed by 1x MVA.HIVA
Number of subjects: 32
Study 16641265 — intervention group
Group type: COMPARATOR
Intervention: 2x MVA.HIVA
Number of subjects: 32
Study 16641265 — intervention group
Group type: COMPARATOR
Intervention: 3x placebo
Number of subjects: 32
Study 14703955 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY (0.25 - 3.5 mg)
Number of subjects: 0
Study 14703955 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY (3.5 mg)
Number of subjects: 0
Study 14703955 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY
Number of subjects: 0
Study 14703955 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY (10 microM)
Number of subjects: 0
Study 14703955 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY (0.1 microM)
Number of subjects: 0
Study 11109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 0
Study 11109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian phase shift and serotonergic hypotheses
Number of subjects: 0
Study 11109298 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular mechanisms of the human circadian clock and retinal phototransduction of light
Number of subjects: 0
Study 8866388 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine management with daily telephone nursing contact (Group 2)
Number of subjects: 64
Study 8866388 — intervention group
Group type: COMPARATOR
Intervention: Routine management without daily telephone nursing contact (Control Group 1)
Number of subjects: 64
Study 8866388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management for all groups
Number of subjects: 64
Study 1335006 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller cuff (mean decrease in CW: AC ratio: 7.4%)
Number of subjects: 1582
Study 1335006 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger cuff (mean increase in CW: AC ratio: 10.2%)
Number of subjects: 1582
Study 1335006 — intervention group
Group type: COMPARATOR
Intervention: Recommended cuff (CW: AC ratio approximately 40%)
Number of subjects: 1582
Study 6373586 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl supplementation (96 mEq/day)
Number of subjects: 23
Study 6373586 — intervention group
Group type: COMPARATOR
Intervention: Non-KCl supplementation
Number of subjects: 23
Study 30075578 — intervention group
Group type: COMPARATOR
Intervention: 20 mg atorvastatin (conventional-dose), n=12
Number of subjects: 24
Study 30075578 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-80 mg atorvastatin (intensive-dose), n=12
Number of subjects: 24
Study 27471782 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention encouraging parents to engage in physical activities with their child, including prone-based play and reducing restrained time in car seats and strollers.
Number of subjects: 802
Study 27471782 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 802
Study 25023813 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1212
Study 25023813 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1212